Sabizabulin on "Short Path to FDA EMA", Will "Serve Critical Roles in the US and Abroad" - Veru (VERU) PT Hiked to $36 at Oppenheimer,

Go back to Sabizabulin on "Short Path to FDA EMA", Will "Serve Critical Roles in the US and Abroad" - Veru (VERU) PT Hiked to $36 at Oppenheimer,

Veru, Inc. (VERU) Extends Yesterday's Gain as Analysts Raise Price Target, Up Another 15%

April 12, 2022 6:36 AM EDT

Veru, Inc. (NASDAQ: VERU) Extends Yesterday's Gain as Analysts Raise Price Target, Up Another 15%

Climbed 180% Yesterday Following Data
... More